Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
about
Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in JapanAdalimumab treatment in Crohn's disease: an overview of long-term efficacy and safety in light of the EXTEND trialSystemic sarcoidosis with bone marrow involvement responding to therapy with adalimumab: a case report.Anti-TNFα therapy in the management of psoriasis: experience of a state referral centerSafety of treatment with biologics for psoriasis in daily practice: 5-year data.Psoriasis, anti-tumor necrosis factor therapy, and tuberculosis: report of three challenging cases and literature review.Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab.Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): results from the CanACT study.An evidence-based review of skin cancer rates on biologic therapies.Effective and sustainable biologic treatment of psoriasis: what can we learn from new clinical data?Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Review of Systemic Immunosuppression for Autoimmune UveitisUpdate on the safety profile of certolizumab pegol in rheumatoid arthritis: an integrated analysis from clinical trials.Effects of tumor necrosis factor alpha blocker adalimumab in experimental spinal cord injury.Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?Evidence-based adverse effects of biologic agents in the treatment of moderate-to-severe psoriasis: Providing clarity to an opaque topic.Effects of tofacitinib on lymphocyte sub-populations, CMV and EBV viral load in patients with plaque psoriasis.Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsTNF Drives Monocyte Dysfunction with Age and Results in Impaired Anti-pneumococcal Immunity.Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis.Tumour necrosis factor blockade for the treatment of erosive osteoarthritis of the interphalangeal finger joints: a double blind, randomised trial on structure modificationMonoclonal antibodies for the treatment of osteoarthritis.A multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.The incidence of tuberculosis in patients treated with certolizumab pegol across indications: impact of baseline skin test results, more stringent screening criteria and geographic region.Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan.Clinical, functional and radiographic consequences of achieving stable low disease activity and remission with adalimumab plus methotrexate or methotrexate alone in early rheumatoid arthritis: 26-week results from the randomised, controlled OPTIMA sAssociation between anti-TNF-α therapy and all-cause mortalityHead-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: findings of a phase IIIb, multinational, prospective, randomized study.Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease.Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.The role of adalimumab in rheumatic and autoimmune disorders: comparison with other biologic agentsTargeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature.Long-term use of adalimumab in the treatment of rheumatic diseases.Incidence density of serious infection, opportunistic infection, and tuberculosis associated with biologic treatment in patients with rheumatoid arthritis - a systematic evaluation of the literature.Head-to-head comparison of subcutaneous abatacept versus adalimumab for rheumatoid arthritis: two-year efficacy and safety findings from AMPLE trial.Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis.Psoriasis and its treatment with adalimumab.Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study.Pharmacotherapy of uveitis.
P2860
Q26829392-B18C0D90-751A-420C-B177-D41B34162F10Q26829488-910AD25C-1750-4FC4-9437-27B99CFF3A8DQ33386650-63592D7D-981D-4A27-9A33-DAEE7C1354EFQ33752359-DB9772EA-DD51-4287-861C-11132C34955FQ33854744-D10BA1D4-7198-4CCA-8CE4-977A6C7ADC68Q33939033-A52ABD3A-45F7-49A8-8E3E-4C09CEF19007Q33953687-E5382F80-B21C-4779-B76E-4527713E6866Q34076916-43442C90-1D99-4001-815D-C33FA8215399Q34107637-D096BB79-E377-41BE-B37E-EC011C3A5B52Q34166896-BB501C8F-45AD-45B6-BF94-E8EF7451952BQ34620323-28E6A589-AC28-4AB7-AE71-B2B56A6DECE6Q34627012-7D1E12C9-152A-4A6C-A61A-C3F437A80B63Q34818636-A9E6C64A-E5FF-4916-9926-58ADDCEC7603Q35133588-CD8898D9-5459-476D-BD5D-875083198E59Q35141922-7BB73DF8-FC91-41DC-AD24-BC3E27C02738Q35606402-976F87D6-E13D-4CEF-90A4-4EF48E2B8649Q35620368-F601774E-D636-4CDC-B54E-575E6C31E026Q35621627-916F851B-1AFB-41C3-83EF-F558060478F4Q35894071-858AA08E-51A8-4DCD-B7C4-DC986C650E46Q35896670-C05AE314-24C2-46D6-9DDE-7429F028F052Q36020188-15AC9CAE-7017-4A4E-A835-83087BDEE9FCQ36113839-585E8128-18B9-490A-8585-92B736515279Q36157440-E50D642C-588E-4902-87BB-1F0D60F1EC1BQ36183786-C368E037-56F5-443B-B602-90DC86C31E61Q36420780-DC7B4893-9195-4A4C-B5F0-62B2DD6CA3B4Q36550842-EDD2B850-9A4B-4CDC-96C6-2BD5255DE10AQ36590690-5662C2FD-2F95-409D-BAFD-48320291BB21Q36610390-38AC85DF-7437-4D61-BBEC-A5D9D4AD9D13Q36677345-3460503B-C2A2-47D9-8215-10E4BF0873FCQ36964382-D4114434-908F-40D5-A900-CFB26696E847Q37189376-0B2F8946-4631-4F1E-B9C3-6FE0A74FD6ADQ37301134-2872B900-ACE6-4DFC-84DD-907F0E7751A1Q37303223-C46B765D-5A1D-49B4-B3D5-2A907C91E788Q37358124-51641C8D-F454-44B3-B67C-219A0902CD92Q37358271-DA1BC32E-BD75-41DC-B77A-20FCB1BC5139Q37465523-DEFF8A56-09CE-4752-AF4E-B20260C602A8Q37567461-693ACA2C-311F-4CD5-B2B1-4DB57E4A7EDEQ37676220-BECBC75F-D222-4819-BE73-B0D3CFB2DB24Q37691205-83616BF8-3D76-407B-B661-A66E37EA7E55Q37724245-98CBA4F8-2FEB-4AF1-A8F0-BC650AD3B756
P2860
Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 15 January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Adalimumab safety and mortalit ...... mediated inflammatory diseases
@en
Adalimumab safety and mortalit ...... ediated inflammatory diseases.
@nl
type
label
Adalimumab safety and mortalit ...... mediated inflammatory diseases
@en
Adalimumab safety and mortalit ...... ediated inflammatory diseases.
@nl
prefLabel
Adalimumab safety and mortalit ...... mediated inflammatory diseases
@en
Adalimumab safety and mortalit ...... ediated inflammatory diseases.
@nl
P2093
P2860
P356
P1476
Adalimumab safety and mortalit ...... mediated inflammatory diseases
@en
P2093
A L Pangan
B A C Dijkmans
R Panaccione
P2860
P304
P356
10.1136/ARD.2008.102103
P407
P577
2009-01-15T00:00:00Z